Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment

Dr. Ghaznavi owns stock in Atai Life Sciences. Dr. Haggerty is on the scientific advisory boards of 4M Therapeutics, Alzheimer’s Drug Discovery Foundation, Entheos Labs, Frequency Therapeutics, Ilios Therapeutics, the Kissick Family Foundation FTD Grant Program, Psy Therapeutics, Souvien Theraputics, and Sensorium Therapeutics; he has received consulting fees from Juvenescence Life, and Biohaven Pharmaceuticals RBNC; he has also received research funding from Atai Life Sciences, COMPASS Pathways, Entheos Labs, JW Pharmaceuticals, Lexicon Pharmaceuticals, Stealth Biotherapeutics, and Vesigen Therapeutics. Dr. King owns stock in Apex Labs, COMPASS Pathways, and Cybin; he is on the scientific advisory board of Apex Labs; and has received consulting fees from Cybin. Dr. Rosenbaum owns stock in Atai Life Sciences, Cerebral Inc., Entheos Labs, Psy Therapeutics, Sensorium Therapeutics, TaraMind, and Terran Biosciences; he is a member of the board of directors for Cerebral Inc., Entheos Labs, Psy Therapeutics, and Sensorium Therapeutics; he is an advisor for TaraMind. Dr. Ruskin owns stock in Ablacor, Celero, Element Science, Infobionic, LuxMed, and NewPace; he has received consulting fees and is a member of the scientific advisory board for Acesion Pharma, Advanced Medical Education, InCarda, Janssen, Sanofi, and Vertex; he holds a patent from Celero Systems.